LEO Pharma Seeks Pediatric Label Expansion for Hand Eczema Cream
Event summary
- LEO Pharma submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for ANZUPGO® (delgocitinib) cream to treat chronic hand eczema in pediatric patients aged 12-17.
- ANZUPGO is currently approved for adults in the U.S. and other regions.
- The sNDA is based on data from the DELTA TEEN Phase 3 trial, which met its primary and key secondary endpoints.
- The DELTA TEEN trial compared ANZUPGO cream to a cream vehicle in pediatric patients with moderate to severe chronic hand eczema.
- The FDA accepted the sNDA on April 15, 2026.
The big picture
LEO Pharma's pursuit of a pediatric label expansion for ANZUPGO reflects a broader trend among pharmaceutical companies to address underserved patient populations and expand the utility of existing drugs. This move positions LEO Pharma to capitalize on a significant unmet medical need, but also exposes them to regulatory scrutiny and potential competition in a niche market. The success of this expansion will be a key indicator of LEO Pharma’s ability to navigate the complexities of pediatric drug development and commercialization.
What we're watching
- Regulatory Risk
- The FDA's approval timeline and any potential requests for additional data will be critical, as the safety and efficacy in pediatric populations haven't been fully evaluated.
- Market Dynamics
- The success of ANZUPGO in the pediatric market will depend on physician adoption and patient access, given the lack of existing approved treatments for this age group.
- Competitive Landscape
- The emergence of alternative therapies or competing JAK inhibitors targeting pediatric hand eczema could erode ANZUPGO's potential market share.
Related topics